Ixekizumab
- Generic Name
- Ixekizumab
- Brand Names
- Taltz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1143503-69-8
- Unique Ingredient Identifier
- BTY153760O
- Background
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A h...
- Indication
Ixekizumab is indicated for the treatment of patients aged six years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is also indicated in adult patients with active psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis with objective signs of inflammation.
- Associated Conditions
- Moderate to Severe Plaque Psoriasis, Active Ankylosing spondylitis, Active Non-radiographic Axial Spondyloarthritis, Active Psoriatic arthritis
- Associated Therapies
- -
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1257
- Registration Number
- NCT02513550
- Locations
- 🇺🇸
David Stoll, M.D., Beverly Hills, California, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT02387801
- Locations
- 🇺🇸
Mount Sinai School of Medicine Dermatology Clinical Trials, New York, New York, United States
Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)
- Conditions
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT01870284
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 417
- Registration Number
- NCT01695239
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.